Molecular Mechanism of Action
The primary site of action for loop diuretics is the epithelium of the thick ascending limb of the loop of Henle. These drugs selectively block the NKCC2 transporter (sodium-potassium-2chloride cotransporter) located on the apical membrane of the cells. Normally, this transporter mediates the coupled entry of one sodium ion ($Na^+$), one potassium ion ($K^+$), and two chloride ions ($2Cl^-$).
Blockade of the NKCC2 protein triggers a cascade of sequential changes:
- Inhibition of electrolyte reabsorption: The primary effect is a sharp decrease in the reabsorption of $Na^+$, $K^+$, and $Cl^-$.
- Osmotic diuresis: Unreabsorbed ions retain water within the tubules along an osmotic gradient, provoking profuse fluid excretion.
- Excretion of divalent cations: Impaired potassium transport alters the transepithelial potential required for passive paracellular reabsorption of magnesium ($Mg^{2+}$) and calcium ($Ca^{2+}$). Long-term magnesium loss leads to hypomagnesemia. Hypocalcemia develops rarely because calcium is compensatorily reabsorbed in the distal tubules.
The efficacy of this drug class is maintained across all variations of blood acid-base balance.
Hemodynamic Effects and Prostaglandins
The therapeutic effect of loop diuretics is not limited to renal mechanisms:
- Stimulation of prostaglandin synthesis: The drugs activate cyclooxygenase-2 (COX-2) expression, leading to an increase in prostaglandin E2 levels, which further inhibits sodium reabsorption.
- Vascular effect: Furosemide and ethacrynic acid exert a vasodilatory effect on pulmonary blood vessels. This decrease in tone occurs before the onset of the diuretic effect.
In acute pulmonary edema, clinical improvement is achieved through two factors: early vasodilation (unloading the pulmonary circulation) and the subsequent reduction in circulating blood volume.
Pharmacokinetic Parameters
The drugs are characterized by a rapid response and a short latency period.
| Drug | Route of Administration | Onset of Action | Duration | Metabolism and Excretion |
|---|---|---|---|---|
| Furosemide | Oral / IV | 30 min / 3–4 min | 3–4 h / 1–2 h | Glucuronidation; renal and GI excretion |
| Bumetanide | Oral | 30–40 min | 4–6 h | Cytochrome P450 system metabolism |
| Ethacrynic acid | Oral / IV | 1 h / 15 min | 6–8 h / 3–4 h | Renal and GI excretion |
Renal elimination occurs via glomerular filtration and active secretion in the proximal segment of the nephron.
Indications and Safety Profile
Clinical Applications:
- Edematous states: Pulmonary edema, cerebral edema, chronic heart failure, liver cirrhosis, angioedema.
- Cardiovascular and obstetric conditions: Hypertensive crisis, severe hypertension, preeclampsia.
- Other indications: Hypercalcemia, forced diuresis in acute poisonings.
Adverse Effects:
- Electrolyte and metabolic disturbances: Hypokalemia (risk of hypokalemic alkalosis), hypomagnesemia, hyperuricemia (decreased uric acid secretion secondary to reduced intravascular volume), hyperglycemia, hyperlipidemia.
- Specific toxicity: Ototoxicity (hearing impairment, most pronounced with ethacrynic acid).
- Allergic history: Furosemide and bumetanide are sulfonamide derivatives. Patients with sulfonamide allergies should be prescribed ethacrynic acid.